The US Food and Drug Administration approved GlaxoSmithKline's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.
Tanzeum will carry a warning on its label that tumors of the thy
Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as it bets on the importance of the continent in driving long-term demand for medicine.
The decision reflects the
An experimental GlaxoSmithKline drug, designed to fight heart disease in a new way, failed to meet its main goal in a major late-stage clinical study, dealing a blow to one of the company's biggest new treatment hopes.
British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.
China announced a nationwide crackdown on the sale of illegal medicine on Wednesday and said it would tighten industry regulation, piling pressure on a sector already reeling from a bribery scandal at British drugmaker GlaxoSmithKline.
Chinese police on Monday accused British drugmaker GlaxoSmithKline of channelling bribes to Chinese officials and doctors through travel agencies for six years to illegally boost sales and to raise the price of its medicines in the country.
A new once-daily Aids drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product.
Both GSK's new drug dolutegravir a
GlaxoSmithKline (GSK) will showcase its product range at the UAE International Dental Conference and Arab Dental Exhibition – AEEDC Dubai 2012, which opened in Dubai today (January 31).
The 16th edition of the show is being held at the Dub
Using GlaxoSmithKline's Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on Wednesday.
An experimental Parkinson's disease drug from GlaxoSmithKline and Impax Laboratories has produced positive results in a second late-stage clinical trial.
The compound, IPX066, which is an extended release ver